Connect with us

Healthcare

Viyash Scientific Limited (viyash) Q4 FY26: Record Ebitda, PAT Surges 306%

Viyash Scientific Limited (VIYASH) reports record Q4 FY26 results with EBITDA surpassing Rs. 200 Cr and PAT up by 306%.

kuldeep yadav tradealone

Published

on

Viyash Scientific Limited Viyash Q4 FY26 Results

Viyash Scientific Limited (VIYASH) has announced its financial results for the period ended March 31, 2026, marking the strongest quarter in the company’s history. The company reported an EBITDA* of ₹ 2,001 million, a significant 63.8% increase from the previous quarter, and a PAT of ₹ 664 million, up by 306%.

Financial Highlights

The consolidated financial highlights for Q4 FY26 show revenues at ₹ 9,200 million, up by 19.1%, and EBITDA* at ₹ 2,001 million, up 63.9%. For FY26, revenues were ₹ 34,203 million, up by 13.8%, and EBITDA* at ₹ 7,025 million, up 59.6%.

Management Commentary

Dr Hari Babu Bodepudi, Managing Director and Group CEO, commented on the company’s performance. He stated, “Fiscal Year 2026 has been a transformative year for Viyash Scientific, marked by the successful integration of our facilities, operations, and corporate functions into one unified platform. Q4 was the strongest quarter in the Company’s history, with merger synergies beginning to reflect meaningfully in our financial performance.”

Forward-Looking Statements

As we enter FY27, we are excited about our product pipeline and growth roadmap. With a significantly deleveraged balance sheet, we are also actively evaluating selective inorganic opportunities to further strengthen our platform and create long-term value.

Source: NSE Corporate Announcement

Fundamental & Technical Analysis of Viyash Scientific Limited

Viyash Scientific Limited belongs to the › sector. Here’s a quick read on where the business and the stock stand today.

VIYASH
Healthcare › Drug Manufacturers - Specialty & Generic
—
60
Fundamental
54
Technical
58
Overall

1W -0.48%
1M +4.59%
3M -6.25%
P/E: 57.8 Cap: Mid
AI-Powered Analysis • TradeAlone
Download the App for in-depth analysis of this stock

Viyash holds in the upper half of its 52-week range, a sign the market backs the stock. Thin margins at 5.4% leave limited room for error — any demand softness or cost spike hits the bottom line hard. Revenue contracts at 3.1% CAGR. That signals structural headwinds, not a short-term blip. Buyers show up with 1.5x the volume of sellers. Moreover, they dominated on 18 of recent sessions versus 12 for sellers — a healthy accumulation pattern. Price climbs recently despite 3.1% revenue growth and a PEG of 99.00. Consequently, either institutions position ahead of improvement or the move fades when earnings disappoint. Treat this as a trading signal, not an investment thesis. Check Fundamentals of Viyash Scientific Limited.

Healthcare

Orchid Pharma Limited Unveils ‘soil to Vialfrom’ Initiative

Orchid Pharma Limited (ORCHPHARMA) reports strong Q2 FY27 results with a 148% surge in EBITDA, highlighting the success of its ‘Soil to VialFROM’ initiative.

seema chauhan author

Published

on

Orchid Pharma Limited Orchpharma Q2 FY27 Results

Orchid Pharma Limited (ORCHPHARMA) has announced impressive financial results for Q2 FY27, marking a significant milestone with its ‘Soil to VialFROM’ initiative. The company’s standalone EBITDA surged by 148% compared to the same period last year, reflecting robust growth and operational efficiency. This remarkable performance underscores the successful integration of Orchid Pharma Limited and Dhanuka Laboratories Ltd., which was sanctioned under the NCLT scheme effective from July 10, 2026.

Financial Performance Highlights

The financial performance for Q2 FY27 showcases a 14% increase in revenue from operations, reaching Rs 341 crore. The gross margin improved to 15%, up from 7% in Q2 FY26. Notably, the EBITDA margin expanded to 12%, highlighting the company’s strong operational leverage. The profit after tax (PAT) for the quarter stood at Rs 37 crore, a substantial improvement from Rs 7 crore in Q2 FY26.

Strategic Growth Initiatives

The ‘Soil to VialFROM’ initiative, which spans from fermentation and biotransformation to finished dosage, is central to Orchid Pharma’s growth strategy. This comprehensive approach not only enhances the company’s capabilities in API manufacturing but also positions it as a leader in the global anti-infectives market. The initiative is expected to drive sustained long-term growth, leveraging Orchid Pharma’s 30 years of expertise in cephalosporin development.

As Orchid Pharma Limited continues to expand its footprint in regulated markets, the company remains committed to innovation and disciplined expansion, aiming to address the growing demand for novel antibiotics and advanced therapeutic solutions.

Source: NSE Corporate Announcement

Fundamental & Technical Analysis of Orchid Pharma Limited

Orchid Pharma Limited belongs to the › sector. Here’s a quick read on where the business and the stock stand today.

ORCHPHARMA
Healthcare › Drug Manufacturers - Specialty & Generic
—
56
Fundamental
78
Technical
68
Overall

1W +4.55%
1M +1.43%
3M -7.42%
P/E: 574.1 Cap: Small
AI-Powered Analysis • TradeAlone
Download the App for in-depth analysis of this stock

Orchid holds in the upper half of its 52-week range, a sign the market backs the stock. Razor-thin margins below 5% make profitability extremely vulnerable — this business needs scale or pricing power urgently. No meaningful dividend — total return is entirely dependent on capital appreciation. The stock gains 1.4% in the last month, recovering from the three-month slide. However, it is too early to call this a confirmed reversal. The stock rises -7.4% in three months on 22.3% revenue growth. As a result, the market gives it more credit than the fundamentals strictly justify. Watch the next quarterly results. If growth accelerates, the move makes sense. If not, expect some gains to unwind. Check Fundamentals of Orchid Pharma Limited.

Continue Reading

GUJTHEM

Gujarat Themis Biosyn Limited Announces Strategic Acquisition of Microbiopharm Japan

Gujarat Themis Biosyn Limited (GUJTHEM) announces acquisition of MicroBiopharm Japan, enhancing its fermentation capabilities and expanding its CDMO services.

kuldeep yadav tradealone

Published

on

Gujarat Themis Biosyn Limited (gujthem) Q4 FY26: Acquisition of Microbiopharm Japan

Gujarat Themis Biosyn Limited (GUJTHEM) announced the acquisition of MicroBiopharm Japan (MBJ), a strategic move aimed at enhancing its fermentation capabilities and expanding its contract development and manufacturing (CDMO) services. The acquisition, valued at JPY 9.5 Bn (INR 557 Cr), is expected to bolster GUJTHEM’s position in the global pharmaceutical market.

Enhanced Fermentation Capabilities

The acquisition of MBJ will provide GUJTHEM access to advanced fermentation, bio-conversion, and precision fermentation technologies. This will enable GUJTHEM to expand its product portfolio to include fermentation-based immunosuppressants, oncology APIs, and anti-infectives.

Diversified Product Portfolio

With the integration of MBJ’s technologies, GUJTHEM aims to transition from anti-TB and anti-infective APIs to specialty small molecules, biologics, and gene therapy products. This diversification will create multiple revenue streams, enhancing the company’s long-term growth prospects.

Global Expansion

The acquisition will also provide GUJTHEM with a global platform, leveraging MBJ’s established customer relationships and manufacturing base in Japan. This will facilitate market entry into Europe and the US, particularly in the plasmid market and CDMO services for immunosuppressants and precision fermentation.

Source: NSE Corporate Announcement

Fundamental & Technical Analysis of Gujarat Themis Biosyn Limited

Gujarat Themis Biosyn Limited belongs to the › sector. Here’s a quick read on where the business and the stock stand today.

GUJTHEM
Healthcare › Drug Manufacturers - Specialty & Generic
CONSOLIDATING DOWN
52
Fundamental
54
Technical
53
Overall

1W -5.37%
1M -3.79%
3M +2.28%
P/E: 80.4 Cap: Small
AI-Powered Analysis • TradeAlone
Download the App for in-depth analysis of this stock

Gujarat posts a 11.4% three-month gain, but softens in the last few weeks. Industry-leading margins of 28.0% reflect exceptional pricing power and operational efficiency. Revenue contracts at 3.8% CAGR. That signals structural headwinds, not a short-term blip. The stock gives back 0.1% in the last month despite a positive three-month run. As a result, the earlier momentum appears to be fading. Revenue grows at 3.8% and the stock moves sideways over three months. Neither side makes a strong case. The next earnings print will likely break this stock out of its current range. Check Fundamentals of Gujarat Themis Biosyn Limited.

Continue Reading

Biotechnology

Dishman Carbogen Amcis Limited (dcal) Q2fy27 Results: Revenue Down 22.8% Yoy

Dishman Carbogen Amcis Limited (NSE: DCAL) reports Q2FY27 results with a 22.8% YoY revenue decline, driven by lower CDMO segment revenue.

Deputy Editor, Equities for tradealone

Published

on

Dishman Carbogen Amcis Limited DCAL Q2fy27 Results

Dishman Carbogen Amcis Limited (NSE: DCAL) has released its financial results for the second quarter of FY27, ending September 30, 2026. The company reported a net revenue of ₹ 6,527 million for Q2FY27, marking a 22.8% year-on-year decline compared to ₹ 8,463 million in Q2FY26. This decline is primarily attributed to lower revenue from the Contract Development and Manufacturing Organisation (CDMO) segment.

Key Financial Highlights

The EBITDA margin for Q2FY27 stood at 9.1%, significantly lower than the 22.8% recorded in the same quarter of the previous fiscal year. The EBITDA for Q2FY27 was ₹ 459.6 million, a sharp decrease from ₹ 1,488.9 million in Q2FY26. The company’s EBITDA margin for the first half of FY27 was 8.9%, down from 21.3% in H1FY26.

Segment Performance

The CDMO segment revenue for Q2FY27 was ₹ 3,887.5 million, a 23.7% decrease from ₹ 5,094.0 million in Q2FY26. The decline is mainly due to lower development revenue and the rescheduling of project deliverables worth approximately CHF 10 million to H2FY27. On the other hand, the marketable molecules segment revenue increased by 6.6% year-on-year to ₹ 1,186.2 million, supported by higher sales of Quaternary compounds.

However, the overall revenue for H1FY27 was ₹ 11,805 million, down 12.9% compared to ₹ 13,607 million in H1FY26. The CDMO segment revenue for H1FY27 was ₹ 9,290.4 million, a 17.1% decrease from ₹ 11,206.4 million in H1FY26, primarily due to lower development revenue. The marketable molecules segment revenue for H1FY27 was ₹ 2,559.7 million, up 2.4% from ₹ 2,400.6 million in H1FY26, driven by higher sales of Quaternary compounds.

As a result, the company’s net profit after tax (PAT) for Q2FY27 was a loss of ₹ 667.3 million, compared to a profit of ₹ 652.7 million in Q2FY26. For H1FY27, the PAT was a loss of ₹ 1,246.1 million, compared to a profit of ₹ 886.8 million in H1FY26.

Source: NSE Corporate Announcement

Fundamental & Technical Analysis of Dishman Carbogen Amcis Limited

Dishman Carbogen Amcis Limited belongs to the › sector. Here’s a quick read on where the business and the stock stand today.

DCAL
Healthcare › Biotechnology
APPROACHING SUPPORT
38
Fundamental
42
Technical
41
Overall

1W -16.68%
1M -7.07%
3M -20.82%
P/E: 135.2 Cap: Small
AI-Powered Analysis • TradeAlone
Download the App for in-depth analysis of this stock

Dishman falls 9.3% over three months and has not found a floor yet. Razor-thin margins below 5% make profitability extremely vulnerable — this business needs scale or pricing power urgently. 2 loss quarter(s) over five years signals earnings fragility — not chronic but worth noting. The stock gains 13.0% in the last month, recovering from the three-month slide. However, it is too early to call this a confirmed reversal. Price climbs recently despite 7.5% revenue growth and a PEG of 99.00. Consequently, either institutions position ahead of improvement or the move fades when earnings disappoint. Treat this as a trading signal, not an investment thesis. Check Fundamentals of Dishman Carbogen Amcis Limited.

Continue Reading

Trending